Search

Displaying results 2221 - 2230 of 8006 in total
  1. Drug

    Inebilizumab

    go.drugbank.com/drugs/DB12530
    ApprovedInvestigational

    [A214280, A214295] On January 16, 2024, inebilizumab also received Health Canada approval for the same indication. … Inebilizumab is cytolytic, resulting in B-cell depletion and offering therapeutic benefit to patients suffering from NMOSD.

  2. Drug

    Berberine

    go.drugbank.com/drugs/DB04115
    ApprovedInvestigationalWithdrawn

    It is relatively toxic parenterally, but has been used orally for various parasitic and fungal infections and as antidiarrheal. … An alkaloid from Hydrastis canadensis L., Berberidaceae. It is also found in many other plants.

    Categories: Heterocyclic Compounds with 4 or More Rings
  3. Drug

    Stannous chloride

    go.drugbank.com/drugs/DB11056
    Approved

    Tin reduces technetium-99m, the active radiological agent, allowing it to form a complex with phosphate-containing moeities [A32700]. … These complexes localize primarily in bone (40-50%) and infracted myocardium (0.01-0.02%/g of tissue) allowing for imaging of areas of altered osteogenesis or necrotic heart tissue [FDA Label].

  4. Drug

    Macimorelin

    go.drugbank.com/drugs/DB13074
    Approved

    Macimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution. … In addition, individuals with may be susceptible to cardiovascular complications from altered structures and function [A31484].

    Categories: Tests for Pituitary Function
  5. Drug

    Lanadelumab

    go.drugbank.com/drugs/DB14597
    ApprovedInvestigational

    [A38676] Lanadelumab was approved for use in patients with hereditary angioedema by the FDA in August 2018,[L4537] followed by Health Canada in October 2018[L49226] and the EMA in November 2018. … [L4538] It is a fully human immunoglobulin, k-light-chain made in recombinant Chinese Hamster Ovary cells.

  6. Drug

    Pegloticase

    go.drugbank.com/drugs/DB09208
    ApprovedInvestigational

    Pegloticase is a porcine recombinant PEGylated uricase indicated for the treatment of chronic gout in adult patients that do not respond to other types of therapies. … [L42425] Pegloticase was approved by the FDA in 2014, and in 2022, the drug label included the co-administration of pegloticase and methotrexate.[L42425]

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Pimavanserin

    go.drugbank.com/drugs/DB05316
    ApprovedInvestigational

    [A232783] It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis thanks to favorable results from a pivotal six-week, randomized … Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders.

  8. Drug

    Acetohexamide

    go.drugbank.com/drugs/DB00414
    ApprovedWithdrawn

    Acetohexamide has been discontinued in the US market.

  9. Drug

    Mavorixafor

    go.drugbank.com/drugs/DB05501
    ApprovedInvestigational

    [L50642] It was first approved by the FDA on April 30, 2024, for the treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a genetic immunodeficiency disorder characterized … by a reduced number of mature neutrophils and lymphocytes.

  10. Drug

    Theophylline

    go.drugbank.com/drugs/DB00277
    ApprovedInvestigational

    A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. … Theophylline is marketed under several brand names such as Uniphyl and Theochron, and it is indicated mainly for asthma, bronchospasm, and COPD.

    Categories: Drugs for Obstructive Airway DiseasesProducts: TEOFILINA RETARD MK 300 MG, TEOFILINA MK RETARD 200 MG CAPSULAS